1 / 29

Osteoporosis

Osteoporosis. UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley. Definition. Osteoporosis and osteopenia are skeletal disorders characterized by low bone mass and microarchitectural fragility. Bone remodelling. Incidence. 1.4 million Canadians affected

polly
Download Presentation

Osteoporosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley

  2. Definition Osteoporosis and osteopenia are skeletal disorders characterized by low bone mass and microarchitectural fragility.

  3. Bone remodelling

  4. Incidence • 1.4 million Canadians affected • 1 in 4 women over age 50 and 1 in 8 men over age 50 • Estimated cost of $1.9 billion to treat osteoporosis and fractures in Canada • 70% of hip fractures are osteoporosis related • www.osteoporosis.ca

  5. What else do you want to know? • Major Risk Factors for Osteoporosis • Age >65 • Vertebral compression # • Family hx of osteoporotic # • >5 months glucocorticoid tx • Malabsorbtion syndrome • 1 hyperparathyroidism • Osteopenia on XR • Hypogonadism • Early menopause (before 45)

  6. Minor Risk Factors Rheumatoid arthritis Hyperthyroidism Prolonged anticonvulsants Prolonged heparin use Body weight <57kg Low calcium intake Excess caffeine (>4 cups/day) Excess alcohol (>2 drinks/day) Smoker

  7. Risk for Fracture Low Bone Mineral Density Prior fragility fracture Long term (>3 months) glucocorticoids Increasing age Family history of osteoporotic fracture

  8. Signs and Symptoms of Osteoporosis Self reported height loss >3cm Weight <51kg Kyphosis - Self reported hump back Grip strength <40lb Tooth count <20

  9. Diagnosis of Osteoporosis Assessment bone microarchitecture – bone biopsy Clinical – fracture in the right context Gold standard…

  10. Bone Mineral Density Assessment • Lotz JC et al. J Biomech Eng 1991 • Marshall D et al. BMJ 1996 • Dual-Energy Xray Absorptiometry (DXA) • Strong correlation between mechanical bone strength DXA measurement of BMD • Strong relationship between fracture risk and BMD measurement

  11. DXA Xray tube generates photon beams at two energy levels Difference in attenuation  BMD determination For comparison, must use same machine

  12. Interpreting a DXA Scan ?

  13. Interpreting the DXA • T-score: • Standard deviation between a pt’s BMD and that of a young adult reference population • Z-score: • Standard deviation between a pt’s BMD and that of an age matched population

  14. Interpreting the DXA – WHO criteria

  15. DXA scan hip / L-spine

  16. Treatment of Osteoporosis Non-drug options Drug options

  17. Weight bearing exercises

  18. Exercises that utilize your own body weight include activities like these, but also include simple activities like walking.

  19. Calcium rich foods

  20. Over the counter vitamins 1200-1500 mg elemental calcium per day 800 IU vitamin D per day

  21. Drugs – “Bisphosphonates” Alendronate Risedronate Etidronate

  22. Dosing Once weekly dosing (70 mg q week) as effective as daily dosing of alendronate with similar side effect profile Rizzoli et al. J Bone Miner Res 2002

  23. Risedronate Similar efficacy Comparable to Alendronate Rosen et al. J Bone Miner. Res. 2005

  24. “Selective Estrogen Receptor Modulators” • Raloxifene • Tamoxifen • Bind with high affinity to Estrogen Receptor and possess tissue selective agonist / antagonist properties  bone specific “estrogen like” action

  25. Bone Forming (Anabolic)Medications Parathyroid Hormone –Teriparatide (brand name - Forteo®). Teriparatide, a type of parathyroid hormone, is approved for the treatment of osteoporosis in postmenopausal women and in men who have very low BMD or are at high risk for a fracture.

  26. Estrogen therapy Fallen out of favor for treatment of osteoporosis since WHI study Increased risk of CHD, VT, breast CA Should not be used first line, except for in women using it for other indications

  27. Quick quiz 1.Are you over 65? 2.Has either of your parents broken a bone after a minor bump or fall? 3.Have you broken a bone after a minor bump or fall? 4.Have you taken glucocorticoid pills (cortisone, prednisone, etc.) for more than three months? 5.Have you lost more than 4 cm (about 1 1/2 inches) in height since age 25 (or 6 cm if you are over 60)? 6.Do you have a tendency to fall? 7.Do you have primary hyperparathyroidism? 8.Do you have a medical condition (such as celiac disease or Crohn's disease) that inhibits absorption of nutrients? 9.Has a recent x-ray suggested you have low bone density (osteopenia)? For Women:10.Did you undergo menopause before age 45? 11.Have your periods stopped for several months or more (other than for pregnancy or menopause)? For Men:12.Have you ever suffered from impotence, lack of libido or other symptoms related to low levels of testosterone? If you're over 50 and have answered yes to any of these questions, Osteoporosis Canada recommends that you talk to your doctor about having a bone mineral density (BMD) test.

  28. Thank you

More Related